Article: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma
| Title | Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma |
|---|---|
| Authors | Suehiro, Y1 4 Wong, CW2 Chirieac, LR1 Kondo, Y6 Shen, L6 Renee Webb, C1 Chan, Y2 Chan, ASY2 Chan, TL2 Wu, TT1 Rashid, A1 Hamanaka, Y5 Hinoda, Y5 Shannon, RL4 Wang, X3 Morris, J3 Issa, JPJ6 Yuen, ST2 Leung, SY2 Hamilton, SR1 3 |
| Issue Date | 2008 |
| Publisher | American Association for Cancer Research. |
| Citation | Clinical Cancer Research, 2008, v. 14 n. 9, p. 2560-2569 [How to Cite?] DOI: http://dx.doi.org/10.1158/1078-0432.CCR-07-1802 |
| Abstract | Purpose: Early events in colorectal tumorigenesis include mutation of the adenomatous polyposis coli (APC) gene and epigenetic hypermethylation with transcriptional silencing of the 06-methylguanine DNA methyltransferase (MGMT), human mut L homologue 1 (hMLH1), and P16ICDKN2A genes. Epigenetic alterations affect genetic events: Loss of MGMT via hypermethylation reportedly predisposes to guanine-to-adenine or cytosine-to-thymine (G:C→A:T) transition mutations in KRAS and P53, and silencing of hMLHI leads to high levels of microsatel-lite instability (MSI-H)/mutator phenotype, suggesting that epigenetic-genetic subtypes exist. Experimental Design: We evaluated the relationships of aberrant methylation of APC, MGMT, hMLH1 P16, N33, and five MINTs to mutations in APC, KRAS, BRAF, and P53 in 208 colorectal carcinomas. Results: We found that APC hypermethylation was age related (P = 0.04), in contrast to the other genes, and did not cluster with CpG island methylator phenotype (CIMP) markers. Hypermethylation of APC concurrently with either MGMT or hMLH1 was strongly associated with occurrence of G-to-A transitions in APC [odds ratio (OR), 26.8; P < 0.0002 from multivariable logic regression model], but C-to-T transitions had no associations. There was no relationship of hypermethylation of any gene, including MGMT, with G-to-A or C-to-T transitions in KRAS or P53, although APC hypermethylation was associated with P53 mutation (P < 0.0002). CIMP with MSI-H due to hMLH1 hypermethylation, or CIMP with loss of MGMT expression in non-MSI-H tumors, was associated with BRAF mutation (OR, 4.5; P < 0.0002). CIMP was also associated with BRAF V600E T-to-A transversion (OR, 48.5; P < 0.0002). Conclusions: Our findings suggest that the heterogeneous epigenetic dysregulation of promoter methylation in various genes is interrelated with the occurrence of mutations, as manifested in epigenetic-genetic subgroups of tumors. © 2008 American Association for Cancer Research. |
| ISSN | 1078-0432 2011 Impact Factor: 7.742 2011 SCImago Journal Rankings: 1.066 |
| DOI | http://dx.doi.org/10.1158/1078-0432.CCR-07-1802 |
| ISI Accession Number ID | WOS:000255616300006 |
| References | References in Scopus |
| dc.contributor.author | Suehiro, Y |
|---|---|
| dc.contributor.author | Wong, CW |
| dc.contributor.author | Chirieac, LR |
| dc.contributor.author | Kondo, Y |
| dc.contributor.author | Shen, L |
| dc.contributor.author | Renee Webb, C |
| dc.contributor.author | Chan, Y |
| dc.contributor.author | Chan, ASY |
| dc.contributor.author | Chan, TL |
| dc.contributor.author | Wu, TT |
| dc.contributor.author | Rashid, A |
| dc.contributor.author | Hamanaka, Y |
| dc.contributor.author | Hinoda, Y |
| dc.contributor.author | Shannon, RL |
| dc.contributor.author | Wang, X |
| dc.contributor.author | Morris, J |
| dc.contributor.author | Issa, JPJ |
| dc.contributor.author | Yuen, ST |
| dc.contributor.author | Leung, SY |
| dc.contributor.author | Hamilton, SR |
| dc.date.accessioned | 2010-09-06T09:41:27Z |
| dc.date.available | 2010-09-06T09:41:27Z |
| dc.date.issued | 2008 |
| dc.description.abstract | Purpose: Early events in colorectal tumorigenesis include mutation of the adenomatous polyposis coli (APC) gene and epigenetic hypermethylation with transcriptional silencing of the 06-methylguanine DNA methyltransferase (MGMT), human mut L homologue 1 (hMLH1), and P16ICDKN2A genes. Epigenetic alterations affect genetic events: Loss of MGMT via hypermethylation reportedly predisposes to guanine-to-adenine or cytosine-to-thymine (G:C→A:T) transition mutations in KRAS and P53, and silencing of hMLHI leads to high levels of microsatel-lite instability (MSI-H)/mutator phenotype, suggesting that epigenetic-genetic subtypes exist. Experimental Design: We evaluated the relationships of aberrant methylation of APC, MGMT, hMLH1 P16, N33, and five MINTs to mutations in APC, KRAS, BRAF, and P53 in 208 colorectal carcinomas. Results: We found that APC hypermethylation was age related (P = 0.04), in contrast to the other genes, and did not cluster with CpG island methylator phenotype (CIMP) markers. Hypermethylation of APC concurrently with either MGMT or hMLH1 was strongly associated with occurrence of G-to-A transitions in APC [odds ratio (OR), 26.8; P < 0.0002 from multivariable logic regression model], but C-to-T transitions had no associations. There was no relationship of hypermethylation of any gene, including MGMT, with G-to-A or C-to-T transitions in KRAS or P53, although APC hypermethylation was associated with P53 mutation (P < 0.0002). CIMP with MSI-H due to hMLH1 hypermethylation, or CIMP with loss of MGMT expression in non-MSI-H tumors, was associated with BRAF mutation (OR, 4.5; P < 0.0002). CIMP was also associated with BRAF V600E T-to-A transversion (OR, 48.5; P < 0.0002). Conclusions: Our findings suggest that the heterogeneous epigenetic dysregulation of promoter methylation in various genes is interrelated with the occurrence of mutations, as manifested in epigenetic-genetic subgroups of tumors. © 2008 American Association for Cancer Research. |
| dc.description.nature | Link_to_subscribed_fulltext |
| dc.identifier.citation | Clinical Cancer Research, 2008, v. 14 n. 9, p. 2560-2569 [How to Cite?] DOI: http://dx.doi.org/10.1158/1078-0432.CCR-07-1802 |
| dc.identifier.citeulike | 5107029 |
| dc.identifier.doi | http://dx.doi.org/10.1158/1078-0432.CCR-07-1802 |
| dc.identifier.epage | 2569 |
| dc.identifier.hkuros | 143514 |
| dc.identifier.isi | WOS:000255616300006 |
| dc.identifier.issn | 1078-0432 2011 Impact Factor: 7.742 2011 SCImago Journal Rankings: 1.066 |
| dc.identifier.issue | 9 |
| dc.identifier.openurl | ![]() |
| dc.identifier.pmid | 18451217 |
| dc.identifier.scopus | eid_2-s2.0-52049085300 |
| dc.identifier.spage | 2560 |
| dc.identifier.uri | http://hdl.handle.net/10722/88292 |
| dc.identifier.volume | 14 |
| dc.language | eng |
| dc.publisher | American Association for Cancer Research. |
| dc.publisher.place | United States |
| dc.relation.ispartof | Clinical Cancer Research |
| dc.relation.references | References in Scopus |
| dc.subject.mesh | Adaptor Proteins, Signal Transducing - genetics - metabolism |
| dc.subject.mesh | Colorectal Neoplasms - genetics - metabolism |
| dc.subject.mesh | CpG Islands - genetics |
| dc.subject.mesh | DNA Methylation |
| dc.subject.mesh | DNA Modification Methylases - genetics - metabolism |
| dc.subject.mesh | DNA Repair Enzymes - genetics - metabolism |
| dc.subject.mesh | Epigenesis, Genetic |
| dc.subject.mesh | Female |
| dc.subject.mesh | Genes, APC |
| dc.subject.mesh | Genes, p53 |
| dc.subject.mesh | Genes, ras |
| dc.subject.mesh | Humans |
| dc.subject.mesh | Male |
| dc.subject.mesh | Middle Aged |
| dc.subject.mesh | Mutation |
| dc.subject.mesh | Nuclear Proteins - genetics - metabolism |
| dc.subject.mesh | Promoter Regions, Genetic |
| dc.subject.mesh | Proto-Oncogene Proteins - genetics - metabolism |
| dc.subject.mesh | Proto-Oncogene Proteins B-raf - genetics - metabolism |
| dc.subject.mesh | Tumor Suppressor Proteins - genetics - metabolism |
| dc.subject.mesh | Wnt Proteins - genetics - metabolism |
| dc.subject.mesh | ras Proteins - genetics - metabolism |
| dc.title | Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma |
| dc.type | Article |
Author Affiliations
- Division of Pathology and Laboratory Medicine
- The University of Hong Kong
- University of Texas M. D. Anderson Cancer Center
- St. Luke's Episcopal Hospital Houston
- Yamaguchi University School of Medicine
- Division of Cancer Medicine


